Jerusalem, 13 January, 2026 (TPS-IL) — Israel’s RevitalVision published positive clinical data showing its digital therapeutic can improve vision in patients with infantile nystagmus, a congenital eye disorder affecting eye movement.
The study, conducted at Shamir Medical Center and published in the British Journal of Ophthalmology, demonstrated significant improvements in visual acuity, contrast sensitivity, and functional vision. Nearly half of treated patients achieved vision sufficient for driving.
RevitalVision’s neuroplasticity-based program offers a non-invasive approach to enhancing cortical visual processing, providing new hope for those with limited treatment options. The therapy is FDA-cleared and delivered digitally under clinician supervision.